

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0004
Drug name and formulations:	Ingenol mebutate gel (Picato®)

Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	No specific additional concerns over other agents
Clinical effectiveness	<i>Established licensed product</i>	Effective against placebo. No direct comparative data, but this is not unusual in this therapeutic area.
Strength of evidence		Similar evidence to other agents for this condition
Cost effectiveness or resource impact	£	Acquisition cost is higher than current treatment options on formulary. No evidence of cost-effectiveness data over other agents. However SMC concluded that the economic case for ingenol mebutate had been demonstrated.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Treatment pathway provided. Would be used in preference to other agents in patients with field change issue, less than 25cm ² , not hyperkeratotic. Also more suitable for elderly patients/ patients where compliance with lengthy treatments is an issue.
National guidance and priorities	<i>NICE, MTRAC</i>	Accepted for use within Scotland and Wales by SMC and AWMSG respectively.
Local health priorities	<i>CCG views</i>	Option for treatment to be initiated in Primary care would reduce referrals to Dermatology clinics. This relies on confidence in diagnosis. Still able to refer to Secondary care if Squamous Cell Carcinoma is suspected.
Equity of access	<i>Equality assessment</i>	Available for all
Stakeholder views	<i>Define wider groups to</i>	N/A

	<i>be engaged</i>	
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN in line with treatment pathway provided (highlight cost/ £)
Implementation requirements:	None required
Implementation monitoring:	None required